MISSION

utilize telephone conference call focus groups were implemented that has allowed successful recruitment of
parent smokers. The project has completed several focus groups. With the success of this mode of focus
group recruitment, the PI intends to use this format to interview a wider sample of subjects in other
geographic locations without travel or time expenses usually associated with using other sites. A revision
was submitted to their IRB to expand their recruitment to include print newspaper advertisements outside
of existing clinical catchment area. To date, 16 former smoking women have been interviewed. Using their
new modality, a greater variety of subjects will be attracted. This project is also designed to become an
integral component of the Dissemination of Best Practices initiative. Message testing with existing CEASE
materials will begin shortly with early focus group participants, as the phone script for live messages are
developed and responses are captured. For the greatest convenience of their participants, selections of
messages will be presented in a mailed packet, and have the packet opened during the phone interview
using a protocol that has been successful in obesity messaging research. In addition, the pilot practices will
be recruited, and the practitioners similarly invited to respond to the messages as they are developed.
FAMRI-IELCAP COLLABORATIVE NETWORK, 2007
Director: Claudia I. Henschke, PhD, MD
The FAMRI-IELCAP Collaborative Network is a multi-disciplinary research and clinical program to
enhance early detection and treatment of lung, cardiovascular, and sinus diseases related to SHS exposure.
The approach encompasses a wide range of disciplines ranging from the use of CT for early detection of
these diseases combined with advanced imaging processing, to laboratory development of key biomarkers.
FAMRI Supported Publications
Lane ME, Yankelevitz DF, Henschke CI, Vazquez MF, Xiang Z, Kimmel M, Kramer A, Wadler S.
Hierarchical cluster analysis of pulmonary fine needle aspirates reveals distinct subgroups of adenocarcinomas
Presented at the 12th International Conference on Screening for Lung Cancer. Nara, Japan, April
2005.
Lane WE, Yankelevitz DF, Henschke CI, Vazquez MF, Xiang Z, Kimmel M, Kramer A, Wadler S. Patterns
of gene expression in pulmonary fine needle aspirates (FNA) with diverse radiographic appearances
Presented at the 11th International Conference on Screening for Lung Cancer. Rome, Italy, October
2005.
Lane ME, Yankelevitz DF, Henschke CI, Vazquez MF, Xiang Z, Kimmel M, Kramer A, Wadler S.
Pulmonary fine needle aspirates (FNA) with diverse radiographic appearances exhibit distinct patterns of
gene expression. Proc Amer Assoc Cancer Res #876 2005.
Lane ME, Yankelevitz DF, Henschke CI, Vazquez MF, Xiang Z, Kimmel M, Kramer A, Wadler S. Patterns
of gene expression in pulmonary fine needle aspirates (FNA) with diverse radiographic appearances
exhibit distinct patterns of gene expression. Proc Amer Assoc Cancer Res 2004 45:5589.
URINARY PGE-M: A NONINVASIVE BIOMARKER OF TOBACCO SMOKE-INDUCED PULMONARY INJURY
Andrew Dannenberg, MD
COPD is one of the leading causes of disability and death worldwide. Unfortunately, tobacco smokeinduced
lung disease, including COPD, is frequently not recognized until severe damage has occurred.
The goal is to develop a simple, noninvasive urinary test of pulmonary inflammation for individuals or
populations exposed to tobacco smoke, including SHS. This approach may facilitate the early detection of
disease and provide the foundation for pharmacological and behavioral strategies that alter the natural
history of tobacco smoke-induced disease. The first specific aims of this project is to compare levels of an
inflammatory biomarker in the urine among groups of individuals that vary in smoke exposure. Levels of
the urinary metabolite will be correlated with severity of pulmonary disease as assessed by spiral computer
tomography and pulmonary function tests. The second specific aim is to evaluate the effect of smoking
reduction and/or cessation on levels of the urinary biomarker of inflammation. The PI hypothesizes that
levels of the urinary marker will decrease in current smokers as they reduce and/or quit smoking and that
it may be useful for personalized risk assessments, to increase motivation among smokers contemplating
quitting and to reinforce the health benefits of reducing tobacco smoke exposure. The third specific aim is
to determine whether the magnitude of elevation of the urinary biomarker of inflammation varies by
genetic polymorphism status for a given level of tobacco smoke exposure. This information may provide
new insights into the link between tobacco smoke, host susceptibility, and pulmonary inflammation.
During the past year, an opportunity presented itself to evaluate the effects of SHS on levels of an
4 6 P A G E